5-Iodo-BZM | 132448-74-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Iodo-BZM
• 英文别名: N-((S)-1-Ethyl-pyrrolidin-2-ylmethyl)-6-hydroxy-3-iodo-2-methoxy-benzamide；N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-6-hydroxy-3-iodo-2-methoxybenzamide
• CAS: 132448-74-9
• 化学式: C₁₅H₂₁IN₂O₃
• 分子量: 404.248
• InChiKey: FKOZYIIIHDNKFQ-JTQLQIEISA-N

物化性质

• 沸点：
  472.4±45.0 °C(Predicted)
• 密度：
  1.510±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2,6-二羟基苯甲酸甲酯 在 氢氧化钾 、 四丁基氟化铵 、 一氯化碘 、 potassium hydrogencarbonate 、 1-羟基苯并三唑一水物 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 四氯化碳 、 二氯甲烷 、 丙酮 为溶剂， 反应 97.0h， 生成 5-Iodo-BZM
  参考文献：
  名称：

  Synthesis and affinity of a possible byproduct of electrophilic radiolabeling of [123I]IBZM

  摘要：

  The iodobenzamide neuroleptic analogue (S)-N-(1-ethylpyrrolidin-2-ylmethyl)-2-hydroxy-5-iodo-6-methoxybenzamide (5-IBZM) was synthesized stereospecifically and its pharmacological properties were compared with the 3-iodo isomer (IBZM) used for imaging D-2 receptors in vivo. The isomer 5-IBZM had 100-fold lower affinity than IBZM and migrated with similar retention time as the byproduct formed during electrophilic iodination of BZM. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.08.063

文献信息

• STABLILIZED AND LYOPHILIZED RADIOPHARMACEUTICAL AGENTS
  申请人：Kuperus H. John

  公开号：US20050281737A1

  公开（公告）日：2005-12-22

  A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization. The preferred composition can be reconstituted “on site” by the addition of a suitable diluent to bring the radiopharmaceutical complex into solution at a desired concentration

  本发明提出了一种新方法，通过一种可快速闪蒸冷冻和脱水放射性药物成分的设备，以稳定、可运输的冻干形式制备放射性诊断放射性药物，从而最大限度地减少自体放射性分解。该方法建议快速冷却和去除环境蒸气，然后在消除液氧爆炸的可能性后进行超低温去除。放射性诊断放射性药物在稳定后无需再进行冷藏或冷冻储存，包括运输。通过添加适当的稀释剂，可在 "现场 "重组优选组合物，使放射性药物复合物以所需浓度进入溶液中。
• Potential neuroleptic agents. 3. Chemistry and antidopaminergic properties of substituted 6-methoxysalicylamides
  作者：Tomas De Paulis、Yatendra Kumar、Lars Johansson、Sten Raemsby、Lennart Florvall、Haakan Hall、Kristina Aengeby-Moeller、Sven Ove Oegren

  DOI：10.1021/jm00147a025

  日期：1985.9

  A series of substituted 6-methoxysalicylamides were synthesized from their corresponding 2,6-dimethoxybenzamides by demethylation of one methoxy group with boron tribromide. Substituted 6-methoxysalicylamides having a lipophilic aromatic substituent in the 3-position para with respect to the methoxy group, e.g. a bromo or an iodo atom or an ethyl or a propyl group, and having an (S)-N-(1-alkyl-2-pyrrolidinyl)methyl moiety as the side chain were found to be potent blockers of [3H]spiperone binding in vitro and potent inhibitors of the apomorphine syndrome in the rat. Similar to remoxipride but in contrast to haloperidol, some of the substituted salicylamides show a 10-20-fold separation between the dose that inhibits hyperactivity and that which inhibits stereotypy. It was concluded that, besides the requirement of a lipophilic substituent in the position para to the methoxy group for antidopamine activity in vivo, the formation of a coplanar six-membered pseudoring involving the amide moiety and the methoxy group is a structural requirement for activity in vitro.
• BOBELDIJK, M.;VERHOEFF, N. P. L. G.;VEKEMANS, J. A. J. M.;BUCK, H. M.;VAN+, J. LABELL. COMPOUNDS AND RADIOPHARM., 28,(1990) N1, C. 1247-1256
  作者：BOBELDIJK, M.、VERHOEFF, N. P. L. G.、VEKEMANS, J. A. J. M.、BUCK, H. M.、VAN+

  DOI：——

  日期：——
• Stabilized and lyophilized radiopharmaceutical agents
  申请人：ANAZAOHEALTH CORPORATION

  公开号：EP1771209B1

  公开（公告）日：2012-08-15
• STABILIZED AND LYOPHILIZED RADIOPHARMACEUTICAL AGENTS
  申请人：Kuperus H. John

  公开号：US20070104646A1

  公开（公告）日：2007-05-10

  A novel method is set out of preparation of radioactive diagnostic radiopharmaceutical in a stable, shippable, lyophilized form by an apparatus designed to rapidly flash freeze and dehydrate a radiopharmaceutical composition to minimize auto radiolysis. The method proposes rapid cooling and removal of ambient vapor, and then ultra cold removal when the potential of explosive liquid oxygen is eliminated. The radioactive diagnostic radiopharmaceutical requires no further cold or refrigerated storage, including with respect to shipping, subsequent to stabilization. The preferred composition can be reconstituted “on site” by the addition of a suitable diluent to bring the radiopharmaceutical complex into solution at a desired concentration.